Evidence map›Paper›PMID 26539835›Full record

ArticleThe New England journal of medicine2015

Soluble Urokinase Receptor and Chronic Kidney Disease.

Salim S Hayek, Sanja Sever, Yi-An Ko, Howard Trachtman, Mosaab Awad, Shikha Wadhwani, Mehmet M Altintas, Changli Wei, Anna L Hotton, Audrey L French and 4 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 240 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 4 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04571372 completednot on this mapstarted 2020, after this paper: background citation

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

TypeobservationalSponsorYonsei UniversityRan2020 to 2025Enrolled222ConditionsSevere Aortic Stenosis or Severe Aortic Regurgitation
NCT06836141 recruitingnot on this mapstarted 2025, after this paper: background citation

Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Typeobservational_patient_registrySponsorRush University Medical CenterRan2025 to 2029Enrolled118ConditionsPrimary Intracerebral HemorrhageArmsMRI, Blood Draw, Cognitive Test
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 4 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.Journal of the American Society of Nephrology : JASN · 2018
    Trial
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Salim S HayekFrom the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine (S.S.H., Y.-A.K., M.A., L.S.S., S.L., A.A.Q.), and the Department of Biostatistics and Bioinformatics, Emory University (Y.-A.K.) - both in Atlanta; the Department of Medicine, Harvard Medical School, Boston, and Division of Nephrology, Massachusetts General Hospital, Charlestown - both in Massachusetts (S.S.); the Department of Pediatrics, NYU Langone Medical Center, New York (H.T.); and the Department of Medicine, Rush University Medical Center (S.W., M.M.A., C.W., A.L.F., J.R.), and the Women's Interagency HIV Study/CORE Center of Cook County (A.L.H., A.L.F.) - both in Chicago.
Sanja Sever
Yi-An Ko
Howard Trachtman
Mosaab Awad
Shikha Wadhwani
Mehmet M Altintas
Changli Wei
Anna L Hotton
Audrey L French
Laurence S Sperling
Stamatios Lerakis
Arshed A Quyyumi
Jochen Reiser
Rush University Medical Center · USCardiovascular Institute Hospital · JPEmory Clinic · USEmory University · USHarvard University · USNYU Langone Health · US

Funding

Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
UAB-MISS WIHS CohortU01AI103401 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KEMPF, MIRJAM-COLETTE, KONKLE-PARKER, DEBORAH J · 2013 to 2018
$11.2M
University of North Carolina Womens Interagency HIV Study UNC WIHSU01AI103390 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADIMORA, ADAORA A · 2013 to 2018
$11.0M
Miami Womens Interagency HIV Study WIHSU01AI103397 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FISCHL, MARGARET A, METSCH, LISA R · 2013 to 2018
$9.6M
NCATS NIH HHS UL1 TR000454NCRR NIH HHS UL1 RR025008NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL089650NHLBI NIH HHS R01 HL113451NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01-AI-103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01-AI-103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01-AI-103401NIAID NIH HHS U01 AI103408NIAID NIH HHS U01-AI-103408NIAID NIH HHS U01-AI-31834NIAID NIH HHS U01-AI-34989NIAID NIH HHS U01-AI-34994NIAID NIH HHS U01-AI-35004NIAID NIH HHS U01-AI-42590NIDDK NIH HHS R01 DK101350
6 · The paper itself

Abstract

backgroundRelatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease.

methodsWe measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox regression after adjustment for demographic and clinical variables.

resultsA higher suPAR level at baseline was associated with a greater decline in the eGFR during follow-up; the annual change in the eGFR was -0.9 ml per minute per 1.73 m(2) among participants in the lowest quartile of suPAR levels as compared with -4.2 ml per minute per 1.73 m(2) among participants in the highest quartile (P<0.001). The 921 participants with a normal eGFR (≥ 90 ml per minute per 1.73 m(2)) at baseline had the largest suPAR-related decline in the eGFR. In 1335 participants with a baseline eGFR of at least 60 ml per minute per 1.73 m(2), the risk of progression to chronic kidney disease in the highest quartile of suPAR levels was 3.13 times as high (95% confidence interval, 2.11 to 4.65) as that in the lowest quartile.

conclusionsAn elevated level of suPAR was independently associated with incident chronic kidney disease and an accelerated decline in the eGFR in the groups studied. (Funded by the Abraham J. and Phyllis Katz Foundation and others.).

Indexed as

Glomerular Filtration RateAgedBiomarkersDisease ProgressionFemaleHumansIncidenceKaplan-Meier EstimateKidneyLinear ModelsMaleMiddle AgedProportional Hazards ModelsProspective StudiesProteinuriaReceptors, Urokinase Plasminogen ActivatorBiomarkersReceptors, Urokinase Plasminogen Activator

Identifiers

PMID26539835
PMCPMC4701036
OpenAlexW2195506720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.